The findings of this study provide insights into the role of hypertension during bevacizumab treatment in exacerbating the proteinuria, which should help healthcare providers better understand the optimal management of anti-VEGF agent-induced proteinuria in clinical practice. Here, VEGFA is linked to Hypertension.